The implementation of targeted therapies for acute myeloid leukaemia (AML) has been
challenging because of the complex mutational patterns within and across patients as well as a …

Acute myeloid leukemia (AML) is a cancer of myeloid-lineage cells with limited therapeutic
options. We previously combined ex vivo drug sensitivity with genomic, transcriptomic, and …

Purpose: On the basis of strong preclinical rationale, we sought to confirm recommended
phase II dose (RP2D) for olaparib, a PARP inhibitor, combined with the AKT inhibitor …

A body of research demonstrates examples of in vitro and in vivo synergy between natural
products and anti-neoplastic drugs for some cancers. However, the underlying biological …

Mechanisms of therapeutic resistance and vulnerability evolve in metastatic cancers as tumor
cells and extrinsic microenvironmental influences change during treatment. To support the …

In a pilot study, we evaluated the feasibility of real-time deep analysis of serial tumor
samples from triple negative breast cancer patients to identify mechanisms of resistance and …

Ferroptosis, a form of programed cell death, can be promoted by inhibitors of the xCT
transporter (erastin) or GPX4 (RSL3). We found that GPX4, but not the xCT transporter, is …

Colorectal cancer (CRC) is a leading cause of cancer-related death. There is an urgent
need for new methods of early CRC detection and monitoring to improve patient outcomes. …

The precision medicine paradigm is centered on therapies targeted to particular molecular
entities that will elicit an anticipated and controlled therapeutic response. However, genetic …

A core tenet of precision oncology is the rational choice of drugs to interact with patient-specific
biological targets of interest, but it is currently difficult for researchers to obtain consistent …